Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

0.3059 +0.0026 (+0.86%)
Streaming Delayed Price Updated: 12:39 PM EDT, Jun 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cybin Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >
Ketamine Ushering in New Era in the Pharmacology Therapies for Neurological Disorders
Palm Beach, FL – July 27, 2022 – For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many lives during the Vietnam... 
Via FinancialNewsMedia
Topics Law Enforcement
Exposures Legal
Research Suggests How Individuals Can Control Unwanted Thoughts
Via Investor Brand Network
BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Scheduled Annual Shareholder Meeting
Via Investor Brand Network
Is It Safe to Smoke DMT?
Via Investor Brand Network
Cybin Announces Date of Annual Meeting of Shareholders
From Cybin Inc.
Via Business Wire
What You Should Know, Do Before Investing in Psychedelics Stocks
Via Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Completes Acquisition of Largest-Ever DMT Study
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Unlocking ‘New Frontiers of Discovery’ with Kernel Flow
Via Investor Brand Network
House Approves Amendments on Psychedelic Therapy in Defense Spending Measure
Via Investor Brand Network
Online Companies Offering Mental Health Services Come Under Spotlight
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB003 Phase 1/2a Clinical Trial Through Clinilabs Begins Enrollment
Via Investor Brand Network
Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
From Clinilabs Drug Development Corporation
Via Business Wire
Congressional Leaders Want Studies to be Conducted on Mental Health Benefits of Psychedelics
Via Investor Brand Network
Topics Law Enforcement
Exposures Legal
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Acquires DMT Study Expected to Accelerate Clinical Development Path of CYB004
Via Investor Brand Network
Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical
From Cybin Inc.
Via Business Wire
Archaeologists Believe Hidden Andean Passageways Were Most Likely Used During Psychedelic Rituals
Via Investor Brand Network
New Study Finds That Probiotics May Be Useful in Fight Against Depression
Via Investor Brand Network
NJ Senate President Introduces Psilocybin Legalization Bill Containing Home-Cultivation Provision
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Adelia Announce Achievement of Milestone
Via Investor Brand Network
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Why More Attention Needs to Be Paid to Paternal Mental Health
Via Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Initial Results from Feasibility Study
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moving Forward with Phase 1/2a Clinical Trial after Receiving Key FDA Approval
Via Investor Brand Network
Exposures Product Safety
Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
New Netflix Series to Explore the Use of Psychedelics for Mental Health
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Business Highlights, FY 2022 Results
Via Investor Brand Network
Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Advances in Precision Medicine Boost Research on Psychedelics
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright 1st Annual Mental Health Conference
Via Investor Brand Network
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright 1st Annual Mental Health Conference
Via Investor Brand Network
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.